Browsing Tag
AstraZeneca
154 posts
Can AstraZeneca’s collaboration with Turbine speed up ADC drug discovery through AI simulation?
AstraZeneca joins hands with AI biotech Turbine to revolutionize antibody-drug conjugate discovery using virtual disease models and lab-in-the-loop design.
Daiichi Sankyo (TSE: 4568) and AstraZeneca (NASDAQ: AZN) surge on Datroway’s historic first-line TNBC survival win
Find out how Datroway’s first-line TNBC survival win could rewrite chemotherapy-first playbooks and accelerate the ADC era in breast cancer—read the full analysis.
GSK stock jumps as insider Luke Miels named next CEO — can he deliver growth before HIV patent cliff hits?
GSK shares rise after naming Luke Miels as CEO-designate to succeed Emma Walmsley on Jan 1, 2026. Find out what investors expect next.
Alibaba Cloud bets on Brazil, Europe, and Asia with new data centers — but can it rival AWS and Microsoft?
Alibaba Cloud expands into Brazil, Europe, and Asia with new data centers, AI programs, and industry partnerships. Find out how it aims to rival AWS and Microsoft.
AstraZeneca just joined the direct-to-consumer drug race — here’s what it means for patients and rivals
AstraZeneca launches AstraZeneca Direct in the U.S. with up to 70% discounts. Explore how this direct-to-consumer model could reshape drug access.
Is pharma nationalism reshaping global R&D? What GSK, Eli Lilly, and AstraZeneca are signaling to the world
GSK, Eli Lilly and AstraZeneca are reshaping global pharma strategy with massive U.S. investments—find out what this means for R&D, supply chains, and policy.
AstraZeneca’s Fasenra misses primary endpoint in COPD trial but keeps investor confidence alive
AstraZeneca’s Fasenra failed to hit its COPD trial endpoint, but stock rose 0.44% as investors bet on pipeline strength and respiratory growth.
AstraZeneca’s Tagrisso redefines survival bar in advanced EGFR-mutant NSCLC
AstraZeneca’s Tagrisso combo extends survival to nearly 4 years in advanced EGFR-mutated lung cancer. Find out what this means for treatment norms.
Daiichi Sankyo launches development of oral triple combination tablets for LDL cholesterol management in Europe
Daiichi Sankyo (TYO: 4568) begins developing oral triple therapy with bempedoic acid, ezetimibe, and statins to transform LDL cholesterol management in Europe.
Can Pfizer’s pipeline offset looming patent cliffs despite a stronger 2025 forecast?
Can Pfizer’s oncology and rare disease pipeline replace billions lost to patent cliffs? Explore how the drugmaker compares with Merck, Bristol Myers, and AstraZeneca.